A股三大指数涨跌不一，截至午间收盘，沪指涨0.16%报3876.4点，深证成指跌0.85%，创业板指跌 1.81%，北证50涨0.64%。全市场成交额10592亿元，较上日成交额放量190亿元，超3600股上涨。盘面 上，商业航天概念股爆发，医药商业、军工装备、IP经济板块涨幅居前；元件、海南、电池板块走低。 中金公司正在筹划吸收合并东兴证券、信达证券，东兴证券涨停，中金涨超5%，信达证券涨4.55%。 ...

格隆汇12月18日｜A股主要指数低开回升，沪指拉升翻红，创业板指、深成指跌幅收窄。光刻机、商业 航天、医药商业、铜链接等方向涨幅居前，沪深京三市上涨个股近3400只。 ...

每经AI快讯，医药板块盘初走强，华人健康涨超15%，鹭燕医药、重药控股涨停，达嘉维康、人民同 泰、漱玉平民等跟涨。 每日经济新闻 ...

Group 1 - The company, Chongqing Pharmaceutical Holdings (重药控股), has confirmed its sales of various medications including Mabalosavir tablets, Oseltamivir, and a series of antibiotics that are used for treating colds and influenza [1]

Group 1 - The company, Chongqing Pharmaceutical Holdings (重药控股), has confirmed its sales of various medications including Mabalosavir tablets, Oseltamivir, and a series of antibiotics that are used for treating colds and influenza [1]

Group 1 - The core announcement is that *ST Meigu (000615) has received court approval for its restructuring plan, which will allow the company to enter the execution phase of the plan and improve its financial structure and operational status [2][8] - The restructuring plan aims to eliminate the company's debt burdens, enhance its corporate image, and focus on the development of its main business [2][8] - If the restructuring is successful, it is expected to significantly impact the company's financial indicators for the year 2025 [2][8] Group 2 - The restructuring process began with a pre-restructuring decision by the Xiangyang Intermediate Court on November 29, 2024, and a restructuring investment agreement was signed on April 23, 2025, between Jiuzhoutong's subsidiary and *ST Meigu [3][9] - A supplementary agreement was signed on September 24, 2025, adjusting the investment terms, where Jiuzhoutong's subsidiary will acquire 435,930,312 shares for a total consideration of 706,207,105.44 yuan [10] - The restructuring investment aligns with Jiuzhoutong's long-term strategic development plan and aims to enhance its core competitiveness in the healthcare sector [4][10] Group 3 - Jiuzhoutong is recognized as the largest private pharmaceutical enterprise in China, with a comprehensive pharmaceutical supply chain service platform [5][10] - Post-restructuring, *ST Meigu plans to leverage the support from its investors to strengthen its existing healthcare services and expand its business into the broader health industry [11]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600998 证券简称：九州通 公告编号：临2025-088 九州通医药集团股份有限公司 关于全资子公司参与重整投资的 奥园美谷科技股份有限公司 重整计划获法院裁定批准的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 ● 相关风险提示：虽然襄阳中院已批准奥园美谷重整计划并终止重整程序，本次重整投资能否顺利实施 完成以及整合效果能否达到投资预期存在一定的不确定性。敬请广大投资者注意投资风险，理性投资。 一、本次重整投资情况概述 2025年4月23日，九州通全资子公司九州产投公司与奥园美谷及其预重整期间临时管理人签订《重整投 资协议》，拟出资673,200,000.00元取得重整后奥园美谷360,000,000股转增股票。公司于2025年4月22日 召开第六届董事会第十三次会议及第六届监事会第十一次会议，审议通过《关于全资子公司签署〈奥园 美谷科技股份有限公司重整投资协议〉的议案》。根据《上海证券交易所股票上市规则》《公司章程》 等相关规定，本次投资事项在公司董 ...

证券之星消息，12月17日医药商业板块较上一交易日上涨1.19%，华人健康领涨。当日上证指数报收于 3870.28，上涨1.19%。深证成指报收于13224.51，上涨2.4%。医药商业板块个股涨跌见下表： 从资金流向上来看，当日医药商业板块主力资金净流入3.3亿元，游资资金净流出830.6万元，散户资金 净流出3.22亿元。医药商业板块个股资金流向见下表： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 ...

Group 1 - The core issue is that Shanghai Pharmaceuticals (Jinzhou) Co., Ltd. has been listed on the military procurement dishonesty list due to violations of "collusion in bidding" [1] - The company is prohibited from participating in military material engineering service procurement activities for three years, effective from December 15, 2025 [2] - The company primarily engages in the distribution and marketing of pharmaceuticals and medical devices, with an annual sales revenue of approximately 90 million yuan [4] Group 2 - Shanghai Pharmaceuticals (Jinzhou) Co., Ltd. was established in 2006 with a registered capital of 10 million yuan, and its major shareholder is Liaoning Province Pharmaceutical Foreign Trade Co., Ltd. [4] - The legal representative of the company was changed from Yuan Kehua to Jiang Ze on July 7 [4]

一心堂12月16日大宗交易平台共发生4笔成交，合计成交量527.59万股，成交金额5972.33万元。成交价 格均为11.32元，相对今日收盘价折价9.37%。 12月16日一心堂大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | 格 | 折溢价（%） | 买方营业部 | 卖方营业部 | | 股） | | （元） | | | | | 264.55 | 2994.71 | 11.32 | -9.37 | 中信证券华南股份有 | 中信证券华南股份有限公司 | | | | | | 限公司云南分公司 | 云南分公司 | | 162.74 | 1842.22 | 11.32 | -9.37 | 中信证券华南股份有 | 国泰海通证券股份有限公司 | | | | | | 限公司云南分公司 | 玉溪玉兴路证券营业部 | | 62.59 | 708.52 | 11.32 | -9.37 | 中信证券华南股份有 | 华泰证券股份有限公司云南 | | | | | | 限公司云南分公司 | 分公司 | ...